Bloomberg Daybreak Weekend with Tom Busby takes a look at some of the stories we'll be tracking in the coming week.

• In the US – a look ahead to next week’s Fed decision.
• In the UK – a look ahead to next week’s Bank of England decision.
• In Asia – a look ahead to next week's Bank of Japan decision.

See omnystudio.com/listener for privacy information.

Stocks fell along with equity-index futures and investors rushed to the safety of havens such as Treasuries after Israel attacked Iran's nuclear program sites. Crude oil jumped more than 9% while gold also rose. We get the latest on what's moving markets from Mary Nicola, Bloomberg MLIV Strategist in Singapore.

Plus - Treasuries rallied across the curve on Thursday, bringing the 10-year yield six basis points lower to around 4.36%. The gains were supported by the second US inflation print in as many days that came in below consensus forecasts, backing the argument for Fed cuts. The dollar hit a three-year low. The producer price index rose 0.1% from a month earlier, compared with the median forecast in a Bloomberg survey of economists that called for a 0.2% increase. A solid sale of long-term US government debt added further impetus for the rally, reducing fears that spiraling deficits are causing investors to shun the bonds. We talk inflation and trade with Natalia Gurushina, Chief Economist for EM Fixed Income Strategy at VanEck.

See omnystudio.com/listener for privacy information.

US equity-index futures dipped along with the dollar after President Donald Trump said he will set unilateral tariff rates within two weeks, dialing up trade tensions once again. The comments come a day after Chinese and US officials struck a positive tone following their talks to dial down trade tensions. Amid US talking with countries including India and Japan to lower the levies, some investors see Trump's comments as an effort to ramp up urgency in talks. We talk markets with Zachary Hill, Head of Portfolio Management at Horizon Investments.

Plus - China's biotech industry is gaining momentum, with Pfizer and Bristol-Myers Squibb making billion-dollar deals with Chinese companies to license experimental cancer drugs. The industry is expected to continue growing, driven by factors such as US President Donald Trump's economic policies, cheaper and easier human testing in China, and an abundance of young and affordable engineering talent. We check in with Shuli Ren, Bloomberg Opinion Columnist, for a closer look at the sector.

See omnystudio.com/listener for privacy information.